Install
Search technical and vendor sites
Relevance tuned for Internet content
The Web search focuses on indexing technical documentation, vendor pages, tutorials, community posts, and authoritative resources. Results are ranked for relevance to Internet topics, with filters for source type, date, and technical depth.
Latest Web Pages
Promoting affordable access to new medicines: a State of Health in the EU webinar
5+ hour, 29+ min ago (115+ words) Access to medicines is under pressure across the EU, as rising prices for new therapies and growing demand test the limits of public budgets. Between 2020 and 2025, Member States implemented wide-ranging reforms to expand coverage, reduce out-of-pocket costs, and sustain innovation....
How to Do Better Research: A Practical Guide for Medical and Community Medicine Researchers
2+ hour, 2+ min ago (1192+ words) From a Good Research Question to Meaningful Evidence By Dr. Shamin Eabenson, MBBS, MD Community …...
Enhertu® Demonstrated a Median Progression-Free Survival of 14.3 Months as First-Line Therapy in Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial
10+ hour, 37+ min ago (848+ words) Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). In the primary endpoint analysis, Enhertu monotherapy significantly reduced…...
Enhertu Shows 14.3-Month PFS in HER2+ Lung Cancer Trial
8+ hour, 52+ min ago (338+ words) Results were presented today during the Presidential Symposium at the IASLC 2026 World Conference on Lung Cancer (#WCLC26) hosted by the International Association for the Study of Lung Cancer in Seoul, South Korea (abstract #PL03.08). In the primary endpoint of PFS, Enhertu monotherapy…...
US push to cut drug prices could mean longer waits for European patients
9+ hour, 11+ min ago (942+ words) Last May, US President Donald Trump pushed to align drug pricing with the lowest levels among other developed nations — so-called most-favoured-nation (MFN) pricing. However, the pricing policy might have negative consequences. European patients might have to wait longer for some…...
News: CMN Moderates Panel Discussion at CSGCT 2026??? In Vivo CRISPR Medicine: From Scientific Promise to Patients at Scale
9+ hour, 4+ min ago (337+ words) CMN Moderates Panel Discussion at CSGCT 2026 – In Vivo CRISPR Medicine: From Scientific Promise to Patients at Scale CRISPR Medicine News CMN Moderates Panel Discussion at CSGCT 2026 – In Vivo CRISPR Medicine: From Scientific Promise to Patients at Scale CMN founder Jens-Ole…...
Otsuka Arm's Lung Cancer Drug Plus Chemotherapy Trial Shows Six-Month Median PFS Benefit
9+ hour, 6+ min ago (41+ words) marketscreener.com Otsuka Holdings Co., Ltd. Otsuka Arm's Lung Cancer Drug Plus Chemotherapy Trial Shows Six-Month Median PFS Benefit Published on 09/14/2026 at 01:08 am EDT...
Think Statins Are Just for Cholesterol? Know Their Bigger Health Benefits
9+ hour, 29+ min ago (294+ words) Statins Beyond Cholesterol: Know Their Wider Health Benefits (Pic: AI image) Statins have long been associated with lowering “bad” cholesterol and reducing the risk of heart attacks and strokes. But researchers are now investigating whether these widely used medicines could…...
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial
10+ hour, 37+ min ago (1000+ words) AstraZeneca and Daiichi Sankyo’s ENHERTU is the first HER2-directed therapy to delay disease progression over standard of care in a Phase III trial in this setting Results were presented today during the Presidential Symposium at the IASLC 2026 World Conference on…...
The System Is Not the Patient
10+ hour ago (316+ words) Across OECD countries, healthcare spending has long grown faster than GDP, while health-adjusted life expectancy has stagnated or declined and up to 20% of spending remains directed to low-value care. Outcome-based care measures success by patient outcomes relative to resources used,…...